Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study

被引：0
作者：
Park, John J.
Gao, Bo
Beecroft, Claire
Wilkinson, Kate Jessica
Parsonson, Andrew
Zhang, Karl
Yan, Xiangyun
Wang, Ni
机构：
[1] Macquarie Univ, Sydney, Australia
[2] Blacktown Hosp, Sydney, Australia
[3] Hollywood Private Hosp, Perth, Australia
[4] Liverpool Hosp, Liverpool, Australia
[5] Alphamab Oncol Ltd, Suzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3038
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study
    Huinink, Wim W. ten Bokkel
    Sufliarsky, Jozef
    Smit, Willem M.
    Spanik, Stanislav
    Wagnerova, Maria
    Hirte, Hal W.
    Kaye, Stan
    Johri, Anandhi R.
    Oza, Amit M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3097 - 3103
  • [42] Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
    Price, T. J.
    Prenen, H.
    Lugowska, I.
    Falchook, G. S.
    Monzon, J. G.
    Arkenau, H. T.
    Chawla, S. P.
    Hui, M. N.
    Kuboki, Y.
    Dziadziuszko, R.
    Ozawa, Y.
    Fernandez, M. E. Elez
    Lima, C. S. P. Rocha
    Subbiah, V.
    Tan, D. S. W.
    Wang, K.
    Hindoyan, A.
    Shi, W.
    Kistler, M.
    Sadraei, N. Hashemi
    ANNALS OF ONCOLOGY, 2021, 32 : S1440 - S1442
  • [43] First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors
    Eskens, F.
    Opdam, F.
    Gort, E.
    Gelderblom, H.
    Prestegarden, L.
    Pico-Navarro, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S758 - S758
  • [44] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Keedy, Vicki L.
    Lenz, Heinz-Josef
    Saltz, Leonard
    Whisenant, Jennifer G.
    Berlin, Jordan D.
    Camacho, Luis H.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 860 - 868
  • [45] Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
    Wu, Y.
    Jing, H.
    Zhang, J.
    Cao, X.
    Li, K.
    Liu, Y.
    Meng, M.
    Li, H.
    Kang, W.
    Li, J.
    Wang, Q.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1497 - S1497
  • [46] Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-Center, Open-Label, Dose-Escalation Study
    Yao, J.
    Chan, J.
    Mita, A.
    Kundu, M.
    Valera, S. Z.
    Unge, P.
    Strosberg, J.
    Wolin, E.
    NEUROENDOCRINOLOGY, 2016, 103 : 76 - 76
  • [47] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    Investigational New Drugs, 2016, 34 : 216 - 224
  • [48] First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
    Hassan, Raffit
    Blumenschein, George R., Jr.
    Moore, Kathleen N.
    Santin, Alessandro D.
    Kindler, Hedy L.
    Nemunaitis, John J.
    Seward, Shelly M.
    Thomas, Anish
    Kim, Stella K.
    Rajagopalan, Prabhu
    Walter, Annette O.
    Laurent, Dirk
    Childs, Barrett H.
    Sarapa, Nenad
    Elbi, Cem
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1824 - +
  • [49] A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.
    Gort, Eelke
    Johnson, Melissa Lynne
    Hwang, Jimmy J.
    Pant, Shubham
    Dunzinger, Ulrich
    Riemann, Kathrin
    Kitzing, Thomas
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Evaluation of the safety and efficacy of JS']JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
    Shen, L.
    Liu, D.
    Park, J. J. W.
    Zhao, Z.
    Gao, B.
    Liu, B.
    Wu, J.
    Zhang, J.
    Zong, H.
    Ruan, J.
    Zhang, X.
    Dai, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S527 - S528
12345